Edition:
United States

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

79.82CHF
11:30am EDT
Change (% chg)

CHF1.90 (+2.44%)
Prev Close
CHF77.92
Open
CHF80.00
Day's High
CHF80.30
Day's Low
CHF79.38
Volume
8,823,832
Avg. Vol
5,353,168
52-wk High
CHF96.20
52-wk Low
CHF71.84

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 1.05
Market Cap(Mil.): CHF219,900.80
Shares Outstanding(Mil.): 2,616.84
Dividend: 2.75
Yield (%): 3.27

Financials

  NOVN.S Industry Sector
P/E (TTM): 31.37 29.30 32.55
EPS (TTM): 2.68 -- --
ROI: 6.14 14.23 13.83
ROE: 9.19 15.46 15.25

CORRECTED-(OFFICIAL)-Novartis mulling $1.5 mln-$5 mln price range for SMA gene therapy

ZURICH, April 24 Novartis Chief Executive Vas Narasimhan said on Wednesday that the Swiss drugmaker is examining a price range for its Zolgensma gene therapy for spinal muscular atrophy (SMA) of between $1.5 million and $5 million per patient.

11:54am EDT

BRIEF-Novartis says 'vast majority' of Lutathera sales in U.S.

* SAYS "VAST MAJORITY" OF RADIOLIGAND THERAPY LUTATHERA'S $106 MILLION Q1 SALES CAME FROM UNITED STATES

11:27am EDT

Novartis shares rise as Swiss drugmaker lifts 2019 profit outlook

ZURICH Swiss drugmaker Novartis raised its 2019 profit target on Wednesday, striking an upbeat tone over a legal fight with peer and partner Amgen and on the safety of a key gene therapy that could win approval next month.

8:58am EDT

Novartis mulling $1.5 mln-$5 mln price range for SMA gene therapy

ZURICH Novartis Chief Executive Vas Narasimhan said on Wednesday that the Swiss drugmaker is examining a price range for its Zolgensma gene therapy for spinal muscular atrophy (SMA) of between $1.5 million and $5 million per patient.

8:58am EDT

UPDATE 2-Novartis shares rise as Swiss drugmaker lifts 2019 profit outlook

* Says "business as usual" for migraine drug despite court case

6:05am EDT

BRIEF-Novartis CEO Says Zolgensma "on track" as May approval date approaches

* CEO SAYS APPROVAL OF ZOLGENSMA GENE THERAPY "ON TRACK" FOR MAY, TAKING ICER REVIEW INTO ACCOUNT WHEN DECIDING ON PRICE

2:07am EDT

Novartis boosts 2019 outlook on rising Cosentyx, Entresto sales

ZURICH, April 24 Swiss drugmaker Novartis on Wednesday raised its 2019 guidance after a first-quarter earnings and sales beat, as revenue from its heart failure drug Entresto and psoriasis medicine Cosentyx continued to grow.

1:24am EDT

BRIEF-Rapha Capital Management Says Participated In A Series C Financing For Poseida Therapeutics

* RAPHA CAPITAL MANAGEMENT, LLC - PARTICIPATION IN A SERIES C FINANCING FOR POSEIDA THERAPEUTICS

Apr 22 2019

Second death in Novartis gene therapy trials under investigation

Novartis AG, which this week announced positive interim trial results for its experimental gene therapy for spinal muscular atrophy, on Friday said investigation is underway into whether a second trial death could be related to the treatment.

Apr 19 2019

Second death in Novartis gene therapy trials under investigation

April 19 Novartis AG, which this week announced positive interim trial results for its experimental gene therapy for spinal muscular atrophy, on Friday said investigation is underway into whether a second trial death could be related to the treatment.

Apr 19 2019

Earnings vs. Estimates